Eli Lilly and Company (NYSE:LLY) Shares Purchased by RDA Financial Network

RDA Financial Network boosted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 12.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,158 shares of the company's stock after acquiring an additional 348 shares during the quarter. RDA Financial Network's holdings in Eli Lilly and Company were worth $2,608,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Patriot Financial Group Insurance Agency LLC increased its position in shares of Eli Lilly and Company by 1.2% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 1,173 shares of the company's stock worth $969,000 after acquiring an additional 14 shares during the period. Revolve Wealth Partners LLC grew its stake in Eli Lilly and Company by 9.7% during the 1st quarter. Revolve Wealth Partners LLC now owns 1,614 shares of the company's stock worth $1,333,000 after purchasing an additional 143 shares in the last quarter. Charter Oak Capital Management LLC raised its position in Eli Lilly and Company by 5.6% in the 1st quarter. Charter Oak Capital Management LLC now owns 1,097 shares of the company's stock valued at $906,000 after purchasing an additional 58 shares in the last quarter. Wedmont Private Capital boosted its stake in shares of Eli Lilly and Company by 3.7% in the 1st quarter. Wedmont Private Capital now owns 14,668 shares of the company's stock valued at $12,114,000 after buying an additional 519 shares during the period. Finally, Regent Peak Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 4.1% during the first quarter. Regent Peak Wealth Advisors LLC now owns 2,666 shares of the company's stock worth $2,202,000 after buying an additional 104 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $770.00 on Friday. The company has a market cap of $729.76 billion, a price-to-earnings ratio of 65.76, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. The stock has a 50 day simple moving average of $770.87 and a 200-day simple moving average of $800.27. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company's revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.58 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.78%. Eli Lilly and Company's payout ratio is currently 48.82%.

Analyst Ratings Changes

Several analysts recently weighed in on LLY shares. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.